Sign in
Taking people in United KingdomPhase 1/2

Tests BAY 3713372 in adults with MTAP-deleted solid tumors

Tests a new drug, BAY 3713372, in adults with certain solid tumors lacking MTAP.

Key facts

Who runs it
Bayer
Where
Manchester and Sutton, United KingdomSee the 2 sitesAlso in 12 other countries, 60 sites
Registry title
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
450 people, planned
Started
21 Mar 2025
Expected to end
18 Jun 2029
Type of study
Interventional, 9 groups
Treatments tested
  • BAY 3713372
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid tumor that has a deletion of both copies of the MTAP gene. It tests a new drug, BAY 3713372.

Age
18 years or older, or the legal age of consent in the country where the study takes place.
Sex
All sexes can join.
Disease stage
Solid tumor with at least one measurable lesion (RECIST 1.1). Performance status (ECOG) of 0 or 1.
Biomarker or test result
Homozygous MTAP deletion, found by molecular testing in a locally certified laboratory.

Main reasons for not taking part

  • Another cancer in the past 2 years, with some exceptions
  • Markedly long QT/QTc interval on heart test (for example QTc above 450 ms)
  • Heart failure above Class II (NYHA)
  • Heart attack less than 6 months before starting the study treatment
  • Unstable angina within 4 weeks before starting the study treatment

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent
  • At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)
  • Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Who cannot take part

  • Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study
  • Cardiac history comprising:; History of congestive heart failure Class >II according to the New York Heart Association Functional Classification; Myocardial infarction less than 6 months before the start of study intervention; Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers
  • Unstable angina within 4 weeks before start of study intervention
  • A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion

Where in United Kingdom

Also in 12 other countries, 60 sites

  • The Christie Hospital | Experimental Cancer Medicine TeamManchester, United KingdomTaking people
  • The Royal Marsden (Surrey) | Oak Foundation Drug Development UnitSutton, United KingdomNot yet recruiting

About the trial

What the trial wants to find out

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.

Read full original descriptionShow less

The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.

For this, the researchers will study and analyze:

* the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.

Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.

The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.

Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.

Participants will visit the study site:

* at least twice before the treatment starts * multiple times when they start taking the treatment * once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason

During the study, the doctors and their study team will:

* check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram * check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan * take tumor samples

The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

The 9 groups in the trial

  • Dose Escalation (Intervention Cohort 1)Treatment being tested

    For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.

    Treatment: BAY 3713372

  • Backfill cohorts in Intervention Cohort 1 (Dose Escalation)Treatment being tested

    Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 1)Treatment being tested

    Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 2)Treatment being tested

    Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 3)Treatment being tested

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 4)Treatment being tested

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 5)Treatment being tested

    Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).

    Treatment: BAY 3713372

  • Dose Expansion (Intervention Cohort 6)Treatment being tested

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.

    Treatment: BAY 3713372

  • Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)Treatment being tested

    A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).

    Treatment: BAY 3713372

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
Plain-language title
Tests BAY 3713372 in adults with MTAP-deleted solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026